The University of Manchester, Manchester, United Kingdom

Group Description

Brief description of legal entity
The Wolfson Molecular Imaging Centre (WMIC) is a central academic institution of the University of Manchester working in the fields of developing, validating and applying molecular imaging technologies in neuroscience and oncology. Equipment: cyclotron, GMP-compliant radiochemistry (12 PET tracers for human use), analytical chemistry, experimental and clinical PET-CT, dedicated high-resolution brain PET scanner, and MRI. Staff: 25 technical and administrative, supporting 20 principal investigators and more than 50 associated researchers. With Prof Karl Herholz (KH) as Associate Director for Neuroscience and Dr Alexander Gerhard (AG), Senior Lecturer in Neurology, the WMIC has strong inter-faculty and interdisciplinary links between basic researchers, medical imaging scientists and clinicians across the University (involving the faculties of medicine, life sciences, chemistry and pharmacy, mathematics and computer sciences, and physics) as well as multiple national and international collaborations.

Main tasks
Neuroscience at the WMIC focuses on in vivo characterisation of neurodegenerative disorders including extensive work on neuroinflammation imaging with the prototypic tracer [11C]PK11195 using a combination of advanced PET and MRI techniques. The Neuroscience Imaging group collaborates very closely with the Cerebral Function Unit at Hope Hospital, a dedicated specialist unit for the diagnosis and treatment of neurodegenerative disorders, and with Prof Stuart Pickering-Brown’s neurogenetics group. Preclinical work concentrates on animal models of acute and chronic neuroinflammation and its correlation with systemic inflammation in collaboration with Professor Nancy Rothwell's group. The close collaboration between these groups allows access to well defined patients with neurodegenerative disorders, fast translation from bench to bedside as well as back-translation of clinical observations to develop more relevant preclinical models of neurodegenerative disorders.

Participation in INMiND: WP3  / WP7 / WP8 (leader) / WP9 / WP10.

Previous experience relevant to INMiND tasks

Extensive experience and expertise in clinical imaging of microglial activation in neurodegenerative disorders with PET (AG), and PET imaging in Neurodegeneration with FDG, amyloid and cholinergic tracers, as documented in publications and participation in FP6/ DiMI.
Coordination of EC-funded International Multicentre Studies, Work package leader of “Early Diagnosis of Neurodegenerative Diseases within the EU-funded Network on Diagnostic Molecular Imaging” and Chief investigator of the EU-funded "Network for Efficiency and Standardisation of Dementia Diagnosis" (NEST-DD) with a comprehensive clinical and neuroimaging digital database of more than 1000 subjects (KH).

University of Manchester
Alexander GERHARD, MD
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313